ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
June 10, 2024 06:30 ET
|
ProKidney
Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both...
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
June 10, 2024 06:00 ET
|
Zymeworks Inc.
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164...
Bitfarms Announces Adoption of Shareholder Rights Plan
June 10, 2024 06:00 ET
|
Bitfarms Ltd.
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 8, 2024, to its short form base shelf prospectus dated November 10, 2023. ...
Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð
June 10, 2024 05:00 ET
|
Oculis Holding AG
ZUG, Sviss, June 10, 2024 (GLOBE NEWSWIRE) -- Virkni lyfsins var greinileg með bætingu á mörgum teiknum (e. signs) augnþurrks í öllum rannsóknarhópnum ásamt því sem aukin áhrif sáust hjá hópi...
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
June 10, 2024 05:00 ET
|
Oculis Holding AG
ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1...
VEON and Kyivstar increase Ukraine investment commitment to USD 1 billion, attend Ukraine Recovery Conference in Berlin
June 10, 2024 05:00 ET
|
VEON Ltd.
Berlin and Kyiv, 10 June 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that VEON, through...
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
June 10, 2024 05:00 ET
|
Oculis Holding AG
Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior...
Food Logistics Names Covenant Logistics Group as Recipient of 2024 Top 3PL & Cold Storage Providers Award
June 10, 2024 00:05 ET
|
Covenant Logistics Group, Inc.
CHATTANOOGA, Tenn., June 10, 2024 (GLOBE NEWSWIRE) -- Food Logistics named Covenant Logistics Group as one of the winners of this year’s Top 3PL & Cold Storage Providers Award, which recognizes...
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
June 09, 2024 19:37 ET
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
June 08, 2024 16:30 ET
|
4D Molecular Therapeutics, Inc.
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher...